STOCK TITAN

Biodesix, Inc. - BDSX STOCK NEWS

Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.

Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.

The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.

Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.

Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.

Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.

Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. This method uses the FDA-cleared Tasso+™ device, enabling capillary blood draws for healthcare providers without convenient access to phlebotomy services or licensed phlebotomists. The device was validated to be administered in minutes, creating efficiencies in the Nodify Lung workflow. Biodesix received approval from the New York State Clinical Laboratory Evaluation Program to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) to participate in Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference. CEO Scott Hutton to present and hold 1x1 meetings. Webcast available for replay on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
conferences
-
Rhea-AI Summary
BDSX Q3 2023 Financial Results: 60% Lung Diagnostic test volume growth, 76% gross profit margin, $10.9M net loss, and $5.4M Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) will release financial results for Q3 2023 on November 7. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
-
Rhea-AI Summary
Biodesix, Inc. announces new data on the clinical utility and real-world impact of Nodify CDT and Nodify XL2 tests in managing lung nodules. The Nodify XL2 test shows a 74% reduction in invasive procedures on benign nodules. The Nodify CDT test improves PET/CT imaging in identifying malignant nodules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences
-
Rhea-AI Summary
Biodesix, Inc. announces two abstracts to be presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Lung Conference on Lung Cancer (WCLC). The first abstract shows that the VeriStrat host immune classifier can predict response to immune checkpoint inhibitor (ICI) regimens in patients with advanced stage non-small cell lung cancer (NSCLC). The second abstract highlights the performance of a pre-surgical Risk of Recurrence test in identifying patients with a high probability of recurrence in early stage NSCLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.77%
Tags
none
Rhea-AI Summary
Biodesix CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.76%
Tags
conferences
-
Rhea-AI Summary
Biodesix announces data demonstrating a 51% relative increase in cancer diagnosis rate for lung nodules with the use of Nodify XL2 test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
none
-
Rhea-AI Summary
Biodesix, Inc. announces record-setting second quarter results with $11.4 million in revenue, a 58% increase YoY, and a gross profit margin of 73%. The company also raised $27.5 million in equity funding through a private placement. Biodesix continues to publish data supporting the value of their lung diagnostics tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
Rhea-AI Summary
Biodesix CEO, Scott Hutton, will present and host investor meetings at the Canaccord Genuity 43rd Annual Growth Conference from August 7-10, 2023. The fireside chat will be webcast live and available for replay on Biodesix's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.17%
Tags
conferences

FAQ

What is the current stock price of Biodesix (BDSX)?

The current stock price of Biodesix (BDSX) is $1.28 as of November 22, 2024.

What is the market cap of Biodesix (BDSX)?

The market cap of Biodesix (BDSX) is approximately 184.7M.

What does Biodesix, Inc. specialize in?

Biodesix specializes in blood-based molecular diagnostic tests that advance care in oncology, focusing primarily on lung disease.

What are some of Biodesix's key products?

Biodesix's key products include VeriStrat® and GeneStrat™, which provide rapid test results within 72 hours without needing tissue samples.

How does Biodesix contribute to precision medicine?

Biodesix contributes to precision medicine by helping physicians provide the right treatment to the right patient at the right time, based on the patient's unique molecular profile.

What services does Biodesix provide to biopharmaceutical companies?

Biodesix provides diagnostic research, clinical trial testing, and the development and commercialization of companion diagnostics to biopharmaceutical companies.

What are Biodesix's primary revenue sources?

Biodesix's revenue mainly comes from providing diagnostic testing services for blood-based lung and COVID-19 tests and offering services to biopharmaceutical companies.

How quickly can Biodesix's tests provide results?

Biodesix's tests, such as VeriStrat® and GeneStrat™, offer results within 72 hours.

Does Biodesix require tissue samples for its tests?

No, Biodesix's tests do not require tissue samples.

What recent achievements has Biodesix made?

Biodesix has recently been in the news for its ongoing projects, partnerships, and significant advancements in diagnostic solutions.

Is Biodesix focused solely on oncology diagnostics?

While Biodesix focuses heavily on oncology diagnostics, it also provides COVID-19 testing services.

What is the ticker symbol for Biodesix, Inc. on the stock market?

The ticker symbol for Biodesix, Inc. is BDSX.

Biodesix, Inc.

Nasdaq:BDSX

BDSX Rankings

BDSX Stock Data

184.74M
70.41M
47.12%
38.64%
0.29%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
LOUISVILLE